The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors
ABSTRACT
Background
In the first‐line (1L) maintenance treatment of newly diagnosed advanced ovarian cancer (OC), poly (ADP‐ribose) polymerase inhibitors (PARPi) have demonstrated significant benefits in progression‐free survival (PFS) and an encouraging trend in overall survival (OS).
Objectives
To provide a summary of advances and evidence regarding the use of PARPi in the maintenance treatment of newly diagnosed advanced OC in the Chinese population.
Search Strategy
Systematic search of PubMed from January 2016 to June 2024.
Selection Criteria
Phase III randomized trials and real‐world studies conducted in China were included.
Main Results
PARPi 1L maintenance studies conducted in China have shown that PARPi can prolong PFS in OC patients with manageable safety. Chinese patients differ from foreign patients in baseline characteristics and safety data. Given the current situation of 1L maintenance therapy in China, recommendations are made for maintenance strategies based on different biomarker status.
Conclusions
PARPi 1L maintenance therapy offers survival benefit to Chinese patients with newly diagnosed advanced OC. OC has become a chronic disease that requires the selection of appropriate maintenance regimens based on multiple factors.